The objective of this multicenter observational study is to describe respiratory sequelae of COVID-19 patients hospitalized for severe pneumonia requiring oxygen supply.
Main objective To assess respiratory sequelae after SARS-CoV-2 infection in hospitalized
patients with severe pneumonia requiring oxygen supply and followed up for 6 months after
hospital discharge (see primary and secondary outcomes).
Secondary objectives
To describe pulmonary sequelae according to :
- the unit in which the patient was hospitalized,
- the maximum oxygen flow rate required during hospitalization,
- McCabe score,
- age,
- tobacco consumption,
- biological data (e.g. blood count, CRP, fibrinogen, LDH, albumin, D-dimer, ferritin),
- number of days from onset of symptoms to hospitalization,
- co-morbidities (e.g. diabetes, hypertension, coronary artery disease/heart failure, mild
to moderate COPD/respiratory failure, overweight),
- concomitant treatments (e.g. non-steroidal anti-inflammatory drugs, corticosteroids,
immunosuppressants, ACE inhibitors)
- specific drug treatments administered to treat COVID-19 infection,
- non-drug treatments (invasive ventilation, non-invasive ventilation, postural treatment)
to manage respiratory disorders of COVID-19 infection.
To assess the impact of factors of social inequality on the severity of COVID-19 infection.
Conduct of research Patients who have been hospitalized for severe pneumonia due to CoV-2
SARS infection will be seen in consultation at approximately 3 and 6 months after hospital
discharge, as per standard practice.
Inclusion criteria:
- Age ≥ 18 years old
- SARS-CoV-2 infection proven by RT-PCR and/or retrospective serology and/or a COVID-19
syndrome with evocative chest CT scan
- Hospitalized for severe pneumonia due to SARS-CoV-2 infection requiring oxygen supply
Exclusion criteria:
- Not hospitalized for a severe COVID-19 infection
- Absence of respiratory symptoms at V1 (3 months after hospital discharge), defined as:
absence of residual exertional dyspnea and persistent pulmonary infiltrates on
follow-up chest radiography at 1 month (if available), transcutaneous oxyhemoglobin
saturation >94% and normal pulmonary auscultation
- Patient with pre-existing chronic lung disease prior to the first episode of COVID-19:
chronic obstructive pulmonary disease confirmed by respiratory function testing with a
forced expiratory volume in one second (FEV1) < 50% and/or a diffusing capacity for
carbon monoxide (DLCO) < 60%, fibrotic lung disease or chronic respiratory failure (on
long-term oxygen therapy)
- Opposition to participation in the study
- Patient under legal protection
- Patient not affiliated to/beneficiary of a social security scheme
Groupe Hospitalier de Mulhouse et de la Région Sud-Alsace
Mulhouse, Alsace, France
Centre Hospitalier de la Côte Basque - Bayonne
Bayonne, France
Centre Hospitalier Métropole Savoie
Chambéry, France
Centre Hospitalier Colmar
Colmar, France
Centre Hospitalier Douai
Douai, France
Centre Hospitalier de Dunkerque
Dunkerque, France
Centre Hospitalier Départemental Vendée - La Roche sur Yon
La Roche-sur-Yon, France
Centre Hospitalier du Mans
Le Mans, France
Centre Hospitalier Robert Boulin - Libourne
Libourne, France
Centre Hospitalier Annecy Genevois
Metz-Tessy, France
Centre Hospitalier Régional Metz-Thioville
Metz, France
Centre Hospitalier Le Raincy Montfermeil
Montfermeil, France
Centre Hospitalier Régional Orléans
Orléans, France
Centre Hospitalier de Soissons
Soissons, France
George-Daniel Calcaianu, MD, Principal Investigator
GHRMSA hospital